The 120-mg/day dose (with the possibility of escalation up to 200 mg/day in case of no response) was identified as the recommended dose for the ADMIRAL study based on findings from the phase 1/2 dose-escalation/expansion CHRYSALIS trial (NCT02014558) of 20–450-mg gilteritinib in a FLT3-mutation–enriched R/R AML patient population [25]. The gene discussed is FLT3; the disease is acute myeloid leukemia.